Skip to contentZ
Zivo Bioscience, Inc.
Z
ZIVOZivo Bioscience, Inc. Q2 2022 · 10-Q
Revenue$0.00$0.00— vs Q2 2021 Net Income-$2.07M-$2.07MN/M vs Q2 2021 EPS, diluted—
Operating Income-$2,067,601N/M The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Zivo Bioscience, Inc. · CIK 1101026 · Engraved from SEC EDGAR
Operating Cash Flowderived-$1,305,728N/M ended Jun 30, 2022 · filed Aug 4, 2022 · 35 d after period end